Sponsor: Alliance for Clinical Trials in Oncology
Sponsor Study ID: A012103
Study Title: OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
CTO #: 103984
NCT Number: NCT05812807
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To evaluate whether observation results in a non-inferior RFS compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pCR after neoadjuvant chemotherapy with pembrolizumab